Nacimbio launches complex programme for antiretroviral drugs production
Cipla agrees to transfer API manufacturing technology reqired for HIV and Hepatitis C drugs.
Russia's National Immunobiological Company (Nacimbio) together with Cipla, have signed a memorandum of understanding on innovative antiviral medical products for HIV and Hepatitis C treatment, and on technology transfer and API manufacturing. New drugs production will help to change therapeutic regimens and substantially increase availability of drugs for Russian patients. By 2019 total market share for anti-HIV drugs will increase to 60%.
Nacimbio CEO Nikolay Semenov and Chandru Chawla, Head of Cipla New Ventures, signed the memorandum of understanding on technology transfer for manufacturing of anti-HIV drugs and drugs for Hepatitis C treatment.
“Today patients undergoing anti-HIV treatment have to take a lot of drugs every day. Our preparations will meet the expectations of Russian patients and will solve this problem. In 2017, we will finalize construction and validation of the manufacturing plant together with Cipla; products will be commercially available in 2018. Total investment in the project will be over 2.8 billion roubles," stated Nacimbio CEO Nikolay Semenov.
“Currently there is no technology for full-cycle manufacturing of HIV treatment drugs in Russia,” said Subhanu Saxena, MD & Global CEO, Cipla. “We are glad that, as a responsible partner together with Nacimbio, we will be able to improve drug availability for patients and make our contribution to the fight against HIV.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.